ChemPartner(SZ:300149)2025-11-14 09:00Group 1: Equity Incentive Plan - The company announced a restricted stock incentive plan on April 2025, with the first grant date set for July 11, 2025, at a price of 3.05 yuan per share, granting 44.56 million shares to 123 recipients including management and key personnel [2][3] - The equity incentive expenses for the first three quarters of 2025 amounted to 3,563.69 million yuan; excluding these expenses, the net profit attributable to shareholders was 42.72 million yuan, a year-on-year increase of 169.29% [3] Group 2: Employee Retention and Stability - The company's recent employee turnover rate is at a healthy level, indicating good team stability [3] Group 3: Collaboration with Investment Funds - The company has established investment funds in collaboration with professional investment institutions to enhance the innovative drug industry, leveraging their investment capabilities and risk control [3] Group 4: Performance Outlook - The company aims for a revenue growth rate of no less than 15% in 2025, with net profit (excluding equity incentive payment expenses) expected to be positive [3]